Table 2. Model Results for Ages 30 and 45 Years.

Characteristic	Cases/100 000			Cost/woman screened, $	Quality-adjusted life years/woman screened	Life-years/woman screened	ICER, $
	Early-stage cancer	Late-stage cancer	Total cancer
Screened at age 30 y
Population screening, base case without cascade testing (95% CR)	143 (111 to 172)	13 642 (12 897 to 14 363)	13 786 (13 040 to 14 512)	14 400 (13 100 to 15 900)	25.7990 (25.6830 to 25.9219)	25.9200 (25.8297 to 26.0395)	NA
Family history–based testing, base case without cascade testing (95% CR)	26 (19 to 34)	13 827 (13 083 to 14 555)	13 853 (13 109 to 14 583)	14 200 (12 800 to 15 600)	25.7964 (25.6799 to 25.9198)	25.9179 (25.8268 to 26.0382)	NA
Incremental
Base case without cascade testing (95% CR)	117 (90 to 141)	−184 (−210 to −152)	−67 (−82 to −51)	240 (200 to 290)	0.0026 (0.0015 to 0.0038)	0.0022 (0.0011 to 0.0032)	No cascade testing: 92 600
Cascade testing (95% CR)	21 (14 to 30)	−29 (−41 to −20)	−8 (−12 to −5)	9 (6 to 13)	0.0003 (0.0002 to 0.0004)	0.0002 (0.0001 to 0.0003)	With cascade testing: 87 700
Screened at age 45 y
Population screening, base case without cascade testing (95% CR)	169 (124 to 203)	12 762 (12 024 to 13 499)	12 930 (12 198 to 13 672)	18 500 (16 800 to 20 300)	21.7245 (21.5895 to 21.8776)	21.8706 (21.7607 to 22.0169)	NA
Family history–based testing, base case without cascade testing (95% CR)	31 (22 to 40)	12 916 (12 181 to 13 657)	12 947 (12 213 to 13 686)	18 300 (16 600 to 20 100)	21.7238 (21.5883 to 21.8768)	21.8698 (21.7597 to 22.0167)	NA
Incremental
Base case without cascade testing (95% CR)	138 (100 to 167)	−154 (−184 to −114)	−16 (−20 to −10)	250 (210 to 290)	0.0007 (0.0000 to 0.0014)	0.0008 (0.0000 to 0.0016)	No cascade testing: 354 500
Cascade testing (95% CR)	21 (14 to 30)	−29 (−41 to −19)	−8 (−11 to −5)	10 (7 to 14)	0.0003 (0.0002 to 0.0004)	0.0002 (0.0001 to 0.0003)	With cascade testing: 268 200

Abbreviations: CR, credible range; ICER, incremental cost-effectiveness ratio; NA, not applicable.